Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 8Dermatologic 3Gastrointestinal 2Other hematologic neoplasm 1Genitourinary 1Breast 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Leukemia, Prolymphocytic, T-Cell 1

Interventions

venetoclax 304Cyclophosphamide 229Cytarabine 199Azacitidine 187fludarabine 180Specimen Handling 136Biopsy 103fludarabine phosphate 97Methotrexate 81Rituximab 78Daunorubicin 77Dexamethasone 75Vincristine 68Whole-Body Irradiation 64Mycophenolic Acid 59Decitabine 57Tacrolimus 55Etoposide 52ibrutinib 51blinatumomab 51Granulocyte Colony-Stimulating Factor 51Busulfan 50obinutuzumab 49Prednisone 49Melphalan 48acalabrutinib 45Idarubicin 45Stem Cell Transplantation 44Injections 44Magnetic Resonance Spectroscopy 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
romidepsin × Other hematologic neoplasm × 1 year × Clear all
NCT02512497 2025-09-19

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
23 enrolled
DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡